Cyclic Peptides Targeting Amyloid-Beta Oligomers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches for treating Alzheimer's disease, particularly in its early stages, lack effective methods to specifically target low molecular weight oligomers of the amyloid-beta protein, which are toxic and contribute to disease progression.
Innovation Solution
Development of cyclic peptides based on amino acid residues 1-14 of the amyloid-beta protein, specifically designed to bind to antibodies that target low molecular weight oligomers, mimicking the hairpin structure of amyloid-beta peptides and inducing an immune response to neutralize these toxic oligomers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If linear peptides based on Aβ regions are used for active immunisation, then the immunogenic construct is simpler to design, but the antibodies generated do not specifically target low molecular weight oligomers
Solution Approach 1:
The peptide is cyclized to change its structural parameters from linear to cyclic conformation. This structural parameter change enables the peptide to specifically mimic the hairpin structure of low molecular weight Aβ oligomers, allowing generated antibodies to specifically recognize and bind to these toxic oligomers while distinguishing them from other Aβ forms
Solution Approach 2:
The cyclic peptide serves as a simplified copy or mimic of the complex hairpin structure found in low molecular weight Aβ oligomers. By copying the essential structural features (hairpin conformation) rather than using the full complex oligomer structure, the invention creates an immunogen that is easier to manufacture yet maintains high specificity for the target oligomers
2Reliability
If cyclic peptides are designed to mimic hairpin structure of Aβ oligomers, then specificity to low molecular weight oligomers is improved, but the peptide synthesis and cyclization process becomes more complex
Solution Approach 1:
The Aβ peptide sequence is segmented into a specific 14-amino acid region (residues 1-14) that contains the essential epitope for antibody recognition. This segmentation allows the peptide to be synthesized as a manageable fragment with cysteine residues positioned for cyclization, balancing structural complexity with synthetic feasibility
Solution Approach 2:
Cysteine residues are introduced as intermediary elements that enable cyclization through disulfide bond formation. These cysteine intermediaries facilitate the formation of the cyclic structure without requiring complex synthetic machinery, as the disulfide bonding occurs spontaneously under appropriate conditions, simplifying the overall cyclization process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclic peptides effectively generate antibodies that specifically recognize and neutralize low molecular weight amyloid-beta oligomers, potentially preventing the formation of plaques and slowing disease progression, as demonstrated by reduced plaque load and improved cognitive function in animal models.
Implementation Method 1
mimicking the hairpin structure of amyloid-beta peptides and inducing an immune response to neutralize these toxic oligomers
Data Source
AI summary
The present invention relates to cyclized peptides based on amino acids 1-14 of amyloid-beta. The cyclic peptides are useful for inducing an immune response and as vaccines for the treatment of neurodegenerative diseases such as Alzheimer's disease.